Some images has been designed using resources from Unsplash & Pixabay & Pexels & Freepik and some icons from Flaticon
跳到主要內容
:::
:::

腫瘤分子調控研究室

TEL: +886-2-28712121*1156
主持人:王夢蓮
2016-present    臺北榮民總醫院醫學研究部高級助理研究員
2014-2015    國立陽明大學研究總中心助理研究員
2008-2013    國立陽明大學生物化學研究所博士後研究員
2007    英國倫敦大學學院生物化學與分子生物學博士


《現職》

臺北榮民總醫院醫學研究部 高級助理研究員

國立陽明交通大學食品安全與健康風險評估研究所 兼任助理教授

《研究興趣》

肺腺癌病人的低存活率主要來自於藥物抗藥性造成的腫瘤復發。因此抗藥性是肺腺癌在臨床上迫切需要解決的關鍵問題。在亞洲,EGFR突變的肺腺癌在肺癌中的盛行率高。EGFR抑制劑(EGFR-TKI)對此種病人的治療效果不錯,然而對EGFR-TKI的抗性經常發生並導致腫瘤復發。我的研究興趣在於了解抗藥性肺癌細胞對腫瘤生長、免疫細胞募集與交互調控、以及對於周邊正常肺細胞癌化的影響與關鍵機轉。

《未來研究方向》
  1. 腫瘤微環境對於腫瘤細胞與免疫細胞交互作用之影響
  2. 癌細胞抗藥性以及轉移浸潤之機制與抑制
  3. 以3D肺類器官模型研究初期癌化現象,以及腫瘤與正常組織間之交互作用。
《執行計畫》

科技部

  1. 探討NKX2.1基因對肺腺癌細胞抗藥性以及腫瘤微環境的調控角色與機制 (MOST 110-2320-B-075 -006 -MY3 多年期)
  1. 探討YTHDF3在肺癌細胞針對第三代EGFR標靶治療產生抗效性作用中的功能與調控機制 (MOST 109-2320-B-075-001)
     
  2. 探討EGFR/Musashi交互作用在肺腺癌抗藥性與免疫調控上之影響機制 (MOST 106-2320-B-075-002)

院內計畫

  1. 建置榮總跨院區人體生物資料庫整合性平台(110VACS-008, 111VACS-008)
     
  2. 探討CXCL5 在免疫細胞與Osimertinib抗藥性肺癌細胞之交互作用中所扮演的角色與功能
     
  3. 建立人工智慧判讀肺癌細胞抗藥性型態變異之平台 (V110C-157)
     
  4. 研究環境低劑量尼古丁在肺腺癌惡化過程中的作用 (V109E-007-4, V111E-001-4, V112E-002-4; 多年期)

嚴慶齡計畫

       剖析Musashi和SOX2在肺腺癌裡的聯結關係及功能 (CI-108-11)
《獎項》

2022 臺北榮總學術論文獎

2020 臺北榮總學術論文獎

專利

專利名稱:METHOD FOR BLOCKING STRESSINDUCED TUMOR PROGRESSION

國別:美國

專利號碼:16/387300

受邀演講

2022年馬來西亞幹細胞與癌症研究聯合科學會議

Joint Scientific Meeting 2022 on Stem Cell and Cancer Research in Malaysia, 2022

Invited speaker

Title: Regulation of Lung Adenocarcinoma Progression by Circular RNAs – a Novel Insight in Tackling with Lung Cancer.

 

2022肺癌國際研討會, 馬來西亞

CCR-CSCR International Webinar Series (1/2022) on Lung Cancer in Malaysia, 2022

Invited speaker

Title: Oncogenic role of circular RNAs in non-small cell lung cancer via EGFR signaling.

 

2020轉譯醫學與創新治療研討會(2020)

2020 International Conference on Translational Medicine and Advanced Therapeutic Medicine in Taipei, 2020.

Section modulator and invited speaker

Title: Novel insight in the Environmental Low-dose Nicotine-induced Lung Cancer Progression.

 

2019國際轉譯醫學與創新治療研討會

International Conference of Translational Medicine and Advanced Therapeutics in Taipei, 2019.

Invited speaker

Title: Crosstalk between cancer cells and environmental stimuli.

 

2019榮陽研發成果發表會

TVGH-NYMU Joint Matchmaking Press Conference in Taipei, 2019.

Invited speaker by GLORIA, National Yang Ming University

Title: Decoy peptide suppress GBM tumor progression and drug-resistance through blocking MSI1/AGO2 interaction.
《近期研究著作》
  1. Circular RNAs Modulate Cancer Hallmark and Molecular Pathways to Support Cancer Progression and Metastasis. Yarmishyn AA, Ishola AA, Chen CY, Verusingam ND, Rengganaten V, Mustapha HA, Chuang HK, Teng YC, Phung VL, Hsu PK, Lin WC, Ma HI, Chiou SH, Wang ML#.Cancers (Basel). 2022 Feb 9;14(4):862. doi: 10.3390/cancers14040862.PMID: 35205610  (corresponding author)
     
  2. Strategic Decoy Peptides Interfere with MSI1/AGO2 Interaction to Elicit Tumor Suppression Effects. Yang YP, Lee AC, Lin LT, Chen YW, Huang PI, Ma HI, Chen YC, Lo WL, Lan YT, Fang WL, Wang CY, Liu YY, Hsu PK, Lin WC, Li CP, Chen MT, Chien CS, Wang ML#.Cancers (Basel). 2022 Jan 20;14(3):505. doi: 10.3390/cancers14030505.PMID: 35158774  (corresponding author)
     
  3. Oncogenic circRNA C190 Promotes Non-Small Cell Lung Cancer via Modulation of the EGFR/ERK Pathway. Ishola AA, Chien CS, Yang YP, Chien Y, Yarmishyn AA, Tsai PH, Chen JC, Hsu PK, Luo YH, Chen YM, Liang KH, Lan YT, Huo TI, Ma HI, Chen MT, Wang ML#, Chiou SH. Cancer Res. 2022 Jan 1;82(1):75-89. doi: 10.1158/0008-5472.CAN-21-1473. Epub 2021 Nov 9. PMID: 34753774 (co-corresponding author)
     
  4. Deep proteogenomic investigations elucidate the NRF2 antioxidant mechanism as a major driving mechanism of lung adenocarcinoma in Asia. Liang KH, Wang ML#. J Chin Med Assoc. 2021 Aug 1;84(8):766-771. doi: 10.1097/JCMA.0000000000000577.PMID: 34183593 (corresponding author)
     
  5. Musashi-1 Regulates MIF1-Mediated M2 Macrophage Polarization in Promoting Glioblastoma Progression. Yang YP, Chien CS, Yarmishyn AA, Chan MS, Lee AC, Chen YW, Huang PI, Ma HI, Lo WL, Chien Y, Lin WC, Wang ML#, Chen MT. Cancers (Basel). 2021 Apr 9;13(8):1799. doi: 10.3390/cancers13081799. PMID: 33918794 (co-corresponding author)
     
  6. Generation of Osimertinib-Resistant Cells from EGFR L858R/T790M Mutant NSCLC Cell Line. Verusingam ND, Chen YC, Lin HF, Liu CY, Lee MC, Lu KH, Cheong SK, Ong AH, Chiou SH, Wang ML#. J Chin Med Assoc. 2021 Mar 1;84(3):248-254. doi: 10.1097/JCMA.0000000000000438. PMID: 33009209 (corresponding author)
     
  7. METTL3-dependent N6-methyladenosine RNA modification mediates the atherogenic inflammatory cascades in vascular endothelium. Chien CS, Li JY, Chien Y, Wang ML, Yarmishyn AA, Tsai PH, Juan CC, Nguyen P, Cheng HM, Huo TI, Chiou SH, Chien S. Proc Natl Acad Sci U S A. 2021 Feb 16;118(7):e2025070118. doi: 10.1073/pnas.2025070118.PMID: 33579825 
     
  8. Musashi-1 promotes cancer stem cell properties of glioblastoma cells via upregulation of YTHDF1. Yarmishyn AA, Yang YP, Lu KH, Chen YC, Chien Y, Chou SJ, Tsai PH, Ma HI, Chien CS, Chen MT, Wang ML#. Cancer Cell Int. 2020 Dec 14;20(1):597. doi: 10.1186/s12935-020-01696-9. PMID: 33317545 (corresponding author) 
     
  9. Low-Dose Nicotine Activates EGFR Signaling via α5-nAChR and Promotes Lung Adenocarcinoma Progression. Wang ML#, Hsu YF, Liu CH, Kuo YL, Chen YC, Yeh YC, Ho HL, Wu YC, Chou TY, Wu CW. Int J Mol Sci. 2020 Sep 17;21(18):6829. doi: 10.3390/ijms21186829. PMID: 32957649 (1st author)
     
  10. Use of Radiographic Features in COVID-19 Diagnosis: Challenges and Perspectives. Chen SG, Chen JY, Yang YP, Chien CS, Wang ML#, Lin LT#. J Chin Med Assoc. 2020 Jul;83(7):644-647. doi: 10.1097/JCMA.0000000000000336. PMID: 32349032 (co-corresponding author)
     
  11. Plasma Level of Circular RNA hsa_circ_0000190 Correlates with Tumor Progression and Poor Treatment Response in Advanced Lung Cancers. Luo YH, Yang YP, Chien CS, Yarmishyn AA, Ishola AA, Chien Y, Chen YM, Huang TW, Lee KY, Huang WC, Tsai PH, Lin TW, Chiou SH, Liu CY, Chang CC, Chen MT, Wang ML#.Cancers (Basel). 2020 Jun 30;12(7):1740. doi: 10.3390/cancers12071740. PMID: 32629833 (corresponding author)
     
  12. Highlight of Immune Pathogenic Response and Hematopathologic Effect in SARS-CoV, MERS-CoV, and SARS-Cov-2 Infection. Liang Y#, Wang ML#, Chien CS, Yarmishyn AA, Yang YP, Lai WY, Luo YH, Lin YT, Chen YJ, Chang PC, Chiou SH. Front Immunol. 2020 May 12;11:1022. doi: 10.3389/fimmu.2020.01022. eCollection 2020. PMID: 32574260 (# equal contribution as 1st author)
     
  13. Dual Supramolecular Nanoparticle Vectors Enable CRISPR/Cas9-Mediated Knockin of Retinoschisin 1 Gene-A Potential Nonviral Therapeutic Solution for X-Linked Juvenile Retinoschisis. Chou SJ, Yang P, Ban Q, Yang YP, Wang ML, Chien CS, Chen SJ, Sun N, Zhu Y, Liu H, Hui W, Lin TC, Wang F, Zhang RY, Nguyen VQ, Liu W, Chen M, Jonas SJ, Weiss PS, Tseng HR, Chiou SH. Adv Sci (Weinh). 2020 Apr 16;7(10):1903432. doi: 10.1002/advs.201903432. eCollection 2020 May. PMID: 32440478
     
  14. A Review of SARS-CoV-2 and the Ongoing Clinical Trials. Tu YF, Chien CS, Yarmishyn AA, Lin YY, Luo YH, Lin YT, Lai WY, Yang DM, Chou SJ, Yang YP, Wang ML#, Chiou SH#. Int J Mol Sci. 2020 Apr 10;21(7):2657. doi: 10.3390/ijms21072657. PMID: 32290293 (co-corresponding author)
     
  15. Musashi-1 promotes stress-induced tumor progression through recruitment of AGO2. Chen HY#, Wang ML#, Laurent B, Hsu CH, Chen MT, Lin LT, Shen J, Chang WC, Hsu J, Hung MC, Chen YW, Huang PI, Yang YP, Li CP, Ma HI, Chen CH, Lin WC, Chiou SH. Theranostics 2020 Jan; 10(1):201-217. doi:10.7150/thno.35895. PMID: 31903115 (# equal contribution as 1st author)
     
  16. Non-coding RNA and Lung Cancer Progression. Adekunle IA, La'ah AS, Le HD, Viet NQ, Yang YP, Chou SJ, Tai HY, Chien CS, Wang ML#. J Chin Med Assoc. 2020 Jan;83(1):8-14. doi: 10.1097/JCMA.0000000000000225. PMID: 31770191 (corresponding author)
     
  17. Ash2l interacts with Oct4-stemness circuitry to promote super-enhancer-driven pluripotency network. Tsai PH#, Chien Y#, Wang ML#, Hsu CH, Laurent B, Chou SJ, Chang WC, Chien CS, Li HY, Lee HC, Huo TI, Hung JH, Chen CH, Chiou SH. Nucleic Acids Res. 2019 Nov 4;47(19):10115-10133. doi: 10.1093/nar/gkz801. PMID: 31555818 (# equal contribution as 1st author)
     
  18. Morphological and Molecular Defects in Human Three-Dimensional Retinal Organoid Model of X-Linked Juvenile Retinoschisis. Huang KC#, Wang ML#, Chen SJ, Kuo JC, Wang WJ, Nhi Nguyen PN, Wahlin KJ, Lu JF, Tran AA, Shi M, Chien Y, Yarmishyn AA, Tsai PH, Yang TC, Jane WN, Chang CC, Peng CH, Schlaeger TM, Chiou SH. Stem Cell Reports. 2019 Nov 12;13(5):906-923. doi: 10.1016/j.stemcr.2019.09.010. Epub 2019 Oct 24. PMID: 31668851 (# equal contribution as 1st author)
     
  19. Tumor Mesenchymal Stromal Cells Regulate Cell Migration of Atypical Teratoid Rhabdoid Tumor through Exosome-Mediated miR155/SMARCA4 Pathway. Yang YP, Nguyen PNN, Ma HI, Ho WJ, Chen YW, Chien Y, Yarmishyn AA, Huang PI, Lo WL, Wang CY, Liu YY, Lee YY, Lin CM, Chen MT, Wang ML#. Cancers (Basel). 2019 May 24;11(5):720. doi: 10.3390/cancers11050720. PMID: 31137686. (corresponding author)
     
  20. Dual Delivery of HNF4α and Cisplatin by Mesoporous Silica Nanoparticles Inhibits Cancer Pluripotency and Tumorigenicity in Hepatoma-Derived CD133-Expressing Stem Cells. Tsai PH#, Wang ML#, Chang JH, Yarmishyn AA, Nhi Nguyen PN, Chen W, Chien Y, Huo TI, Mou CY, Chiou SH. ACS Appl Mater Interfaces. 2019 Jun 5;11(22):19808-19818. doi: 10.1021/acsami.9b04474. Epub 2019 May 16. PMID: 31066542 (# equal contribution as 1st author)

最後更新:

回到最上